Meningococcal bivalent vaccine group B OMV (Finlay/GlaxoSmithKline)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameMeningococcal bivalent vaccine group B OMV (Finlay/GlaxoSmithKline)
Drug Alias NameBivalent MenB OMV vaccine - Finlay/GlaxoSmithKline
ClassificationVaccines > Biological material > Bacterial vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMeningococcal Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcFinlay Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsMeningococcal Infections

Other Information

ATC CodeN/A
Related LinksN/A